留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

绝经激素治疗与女性恶性肿瘤

周文杰 吴洁

周文杰, 吴洁. 绝经激素治疗与女性恶性肿瘤[J]. 协和医学杂志, 2021, 12(2): 157-162. doi: 10.12290/xhyxzz.20200285
引用本文: 周文杰, 吴洁. 绝经激素治疗与女性恶性肿瘤[J]. 协和医学杂志, 2021, 12(2): 157-162. doi: 10.12290/xhyxzz.20200285
ZHOU Wen-jie, WU Jie. Menopausal Hormone Therapy and Female Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 157-162. doi: 10.12290/xhyxzz.20200285
Citation: ZHOU Wen-jie, WU Jie. Menopausal Hormone Therapy and Female Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 157-162. doi: 10.12290/xhyxzz.20200285

绝经激素治疗与女性恶性肿瘤

doi: 10.12290/xhyxzz.20200285
基金项目: 

国家自然科学基金面上项目 81771540

江苏省妇幼保健重点学科 FXK201701

江苏省医学创新团队 CXTDA2017004

详细信息
    通讯作者:

    吴洁  电话:025-68308648,E-mail:wujiemd@126.com

  • 中图分类号: R71

Menopausal Hormone Therapy and Female Cancer

Funds: 

National Natural Science Foundation of China 81771540

Jiangsu Province Maternal and Child Health Project FXK201701

Jiangsu Medical Innovation Team Project CXTDA2017004

More Information
    Corresponding author: WU Jie  Tel: 86-25-68308648, E-mail: wujiemd@126.com
  • 摘要: 医学的快速发展显著提高了恶性肿瘤患者的生存率和生存时间,因此,越来越多的女性恶性肿瘤幸存者将经历自然绝经或由于肿瘤治疗导致的早发性卵巢功能不全(premature ovarian insufficiency,POI)。自然绝经或POI带来的雌激素水平缺乏,可引起潮热、出汗、失眠、泌尿生殖道萎缩等一系列症状,远期负面影响包括心血管疾病、骨质疏松等风险增加,严重影响女性生活质量。因此,绝经激素治疗(menopausal hormone therapy,MHT)在女性恶性肿瘤幸存者中的应用日益受到关注。本文将对MHT与女性恶性肿瘤的关系及恶性肿瘤幸存者应用MHT的利弊进行分析。
    作者贡献:周文杰负责资料收集、论文撰写;吴洁负责选题构思、论文修订。
    利益冲突:  无
  • [1] 中华医学会妇产科学分会绝经学组. 中国绝经管理与绝经激素治疗指南(2018)[J]. 协和医学杂志, 2018, 9: 512-525. doi:  10.3969/j.issn.1674-9081.2018.06.007

    Menopause Group, Obstertrics and Gynecology Branch, Chinese Medical Association. 2018 Chinese Guideline on Menopause Management and Menopause Hormone Therapy[J]. Xie He Yi Xue Za Zhi, 2018, 9: 512-525. doi:  10.3969/j.issn.1674-9081.2018.06.007
    [2] 中华医学会妇产科学分会绝经学组. 早发性卵巢功能不全的激素补充治疗专家共识[J]. 中华妇产科杂志, 2016, 51: 881-886 doi:  10.3760/cma.j.issn.0529-567x.2016.12.001

    Menopause Group, Obstertrics and Gynecology Branch, Chinese Medical Association. 2016 Consensus of hormone replacement therapy for premature ovarian insufficiency[J]. Zhonghua Fu Chan Ke Za Zhi, 2016, 51: 881-886. doi:  10.3760/cma.j.issn.0529-567x.2016.12.001
    [3] Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial[J]. JAMA, 2002, 288: 321-333. doi:  10.1001/jama.288.3.321
    [4] Chlebowski RT, Rohan TE, Manson JE, et al. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials[J]. JAMA Oncol, 2015, 1: 296-305. doi:  10.1001/jamaoncol.2015.0494
    [5] Crandall CJ, Hovey KM, Andrews C, et al. Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women' s Health Initiative Observational Study[J]. Menopause, 2017, 24: 1145-1153. doi:  10.1097/GME.0000000000000899
    [6] Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial[J]. JAMA, 2003, 289: 3243-3253. doi:  10.1001/jama.289.24.3243
    [7] Stahlberg C, Pedersen AT, Andersen ZJ, et al. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy[J]. Br J Cancer, 2004, 91: 644-650. doi:  10.1038/sj.bjc.6601996
    [8] Kotsopoulos J, Gronwald J, Karlan BY, et al. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers[J]. JAMA Oncol, 2018, 4: 1059-1065. doi:  10.1001/jamaoncol.2018.0211
    [9] Stute P, Wildt L, Neulen J. The impact of micronized progesterone on breast cancer risk: a systematic review[J]. Climacteric, 2018, 21: 111-122. doi:  10.1080/13697137.2017.1421925
    [10] Fait T. Menopause hormone therapy: latest developments and clinical practice[J]. Drugs Context, 2019, 8: 212551.
    [11] Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped[J]. Lancet, 2004, 363: 453-455. doi:  10.1016/S0140-6736(04)15493-7
    [12] von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: The Stockholm randomized trial[J]. J Natl Cancer Inst, 2005, 97: 533-535. doi:  10.1093/jnci/dji071
    [13] Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors[J]. J Natl Cancer Inst, 2008, 100: 475-482. doi:  10.1093/jnci/djn058
    [14] Fahlén M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 years follow up of the Stockholm randomised trial[J]. Eur J Cancer, 2013, 49: 52-59. doi:  10.1016/j.ejca.2012.07.003
    [15] Marsden J, Marsh M, Rigg A. British Menopause Society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women treated for early breast cancer[J]. Post Reprod Health, 2019, 25: 21-32. doi:  10.1177/2053369118824920
    [16] Sjögren LL, Mørch LS, Løkkegaard E. Hormone replace-ment therapy and the risk of endometrial cancer: a systematic review[J]. Maturitas, 2016, 91: 25-35. doi:  10.1016/j.maturitas.2016.05.013
    [17] Chapman JA, DiSaia PJ, Osann K, et al. Estrogen replacement in surgical stage Ⅰ and Ⅱ endometrial cancer survivors[J]. Am J Obstet Gynecol, 1996, 175: 1195-1200. doi:  10.1016/S0002-9378(96)70027-3
    [18] Suriano KA, McHale M, McLaren CE, et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study[J]. Obstet Gynecol, 2001, 97: 555-560.
    [19] Barakat RR, Bundy BN, Spirtos NM, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage Ⅰ or Ⅱ endometrial cancer: a Gynecologic Oncology group study[J]. J Clin Oncol, 2006, 24: 587-592. doi:  10.1200/JCO.2005.02.8464
    [20] Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis Randomized double-blind trial of estrogen replacement therapy versus placebo in stage Ⅰ or Ⅱ endometrial cancer: a Gynecologic Oncology group study[J]. Eur J Cancer, 2014, 50: 1628-1637. doi:  10.1016/j.ejca.2014.03.006
    [21] Chapman JA, DiSaia PJ, Osann K, et al. Estrogen replacement in surgical stage Ⅰ and Ⅱ endometrial cancer survivors[J]. Am J Obstet Gynecol, 1996, 175: 1195-1200. doi:  10.1016/S0002-9378(96)70027-3
    [22] Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2018, 16: 170-199. doi:  10.6004/jnccn.2018.0006
    [23] Del Carmen MG, Rice LW. Management of menopausal symptoms in women with gynecologic cancers[J]. Gynecol Oncol, 2017, 146: 427-435. doi:  10.1016/j.ygyno.2017.06.013
    [24] Jaakkola S, Pukkala E, K Lyytinen H, et al. Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer[J]. Int J Cancer, 2012, 131: E537-E543. doi:  10.1002/ijc.27321
    [25] Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment[J]. Gynecol Oncol, 1987, 26: 169-177. doi:  10.1016/0090-8258(87)90270-8
    [26] Deli T, Orosz M, Jakab A. Hormone Replacement Therapy in Cancer Survivors-Review of the Literature[J]. Pathol Oncol Res, 2020, 26: 63-78. doi:  10.1007/s12253-018-00569-x
    [27] Collaborative Group On Epidemiological Studies Of Ovarian Cancer, Beral V, Gaitskell K, et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies[J]. Lancet, 2015, 385: 1835-1842. doi:  10.1016/S0140-6736(14)61687-1
    [28] Manson JE, Chlebowski RT, Stefanick ML, et al. Meno-pausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials[J]. JAMA, 2013, 310: 1353-1368. doi:  10.1001/jama.2013.278040
    [29] Rasmussen ELK, Hannibal CG, Dehlendorff C, et al. Parity, infertility, oral contraceptives, and hormone replace-ment therapy and the risk of ovarianserous borderline tumors: A nationwide case-control study[J]. Gynecol Oncol, 2017, 144: 571-576. doi:  10.1016/j.ygyno.2017.01.002
    [30] Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial[J]. Cancer, 1999, 86: 1013-1018. doi:  10.1002/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1
    [31] Eeles RA, Morden JP, Gore M, et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial[J]. J Clin Oncol, 2015, 33: 4138-4144. doi:  10.1200/JCO.2015.60.9719
    [32] Pergialiotis V, Pitsouni E, Prodromidou A, et al. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis[J]. Menopause, 2016, 23: 335-342. doi:  10.1097/GME.0000000000000508
    [33] Kuhle CL, Kapoor E, Sood R, et al. Menopausal hormone therapy in cancer survivors: A narrative review of the literature[J]. Maturitas, 2016, 92: 86-96. doi:  10.1016/j.maturitas.2016.07.018
    [34] Biglia N, Bounous VE, Sgro LG, et al. Treatment of climacteric symptoms in survivors of gynaecological cancer[J]. Maturitas, 2015, 82: 296-298. doi:  10.1016/j.maturitas.2015.07.006
    [35] Lin KJ, Cheung WY, Lai JY, et al. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer[J]. Int J Cancer, 2012, 130: 419-430. doi:  10.1002/ijc.26026
    [36] Murphy N, Strickler HD, Stanczyk FZ, et al. A prospective evaluation of endogenous sex hormone levels and colorectal cancer risk in postmenopausal women[J]. J Natl Cancer Inst, 2015, 107: djv210. doi:  10.1093/jnci/djv210
    [37] Caiazza F, Ryan EJ, Doherty G, et al. Estrogen receptors and their implications in colorectal carcinogenesis[J]. Front Oncol, 2015, 5: 19. http://europepmc.org/abstract/med/25699240
    [38] Adami HO, Persson I, Hoover R, et al. Risk of cancer in women receiving hormone replacement therapy[J]. Int J Cancer, 1989, 44: 833-839. doi:  10.1002/ijc.2910440515
    [39] Montella M, D'Arena G, Crispo A, et al. Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma[J]. Int J Endocrinol, 2015, 2015: 854530.
    [40] Hassan MM, Botrus G, Abdel-Wahab R, et al. Estrogen Replacement Reduces Risk and Increases Survival Times of Women with Hepatocellular Carcinoma[J]. Clin Gastroenterol Hepatol, 2017, 15: 1791-1799. doi:  10.1016/j.cgh.2017.05.036
    [41] Hsu LH, Chu NM, Kao SH. Estrogen, Estrogen Receptor and Lung Cancer[J]. Int J Mol Sci, 2017, 18: 1713. doi:  10.3390/ijms18081713
    [42] Chlebowski RT, Anderson GL, Manson JE, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial[J]. J Natl Cancer Inst, 2010, 102: 1413-1421. doi:  10.1093/jnci/djq285
    [43] Ganti AK, Sahmoun AE, Panwalkar AW, et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer[J]. J Clin Oncol, 2016, 24: 59-63. http://jjco.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=jco&resid=24/1/59
    [44] Li Q, Kopecky KJ, Mohan A, et al. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia[J]. Clin Cancer Res, 1999, 5: 1077-1084. http://www.ncbi.nlm.nih.gov/pubmed/10353741
    [45] Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate-or high-grade B-cell non-Hodgkin's lymphoma in women[J]. J Clin Oncol, 2001, 19: 1381-1387. doi:  10.1200/JCO.2001.19.5.1381
    [46] Medina KL, Strasser A, Kincade PW. Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors[J]. Blood, 2000, 95: 2059-2067. doi:  10.1182/blood.V95.6.2059
    [47] Yang X, Wang C, He X, et al. Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases[J]. Climacteric, 2017, 20: 268-273. doi:  10.1080/13697137.2017.1309382
    [48] Tauchmanovà L, Selleri C, De Rosa G, et al. Estrogen-progestin therapy in women after stem cell transplant: our experience and literature review[J]. Menopause, 2007, 14: 320-330. doi:  10.1097/01.gme.0000232032.84788.8c
    [49] Sturniolo G, Zafon C, Moleti M, et al. Immunohistochemical Expression of Estrogen Receptor-α and Progesterone Receptor in Patients with Papillary Thyroid Cancer[J]. Eur Thyroid J, 2016, 5: 224-230. doi:  10.1159/000452488
    [50] O'Shea T, Crowley RK, Farrell M, et al. Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia[J]. Endocrinol Diabetes Metab Case Rep, 2016, 2016: 16-0054.
    [51] Pines A. Hormone therapy and brain tumors[J]. Climacteric, 2011, 14: 215-216. doi:  10.3109/13697137.2010.533615
    [52] Benson VS, Kirichek O, Beral V, et al. Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis[J]. Int J Cancer, 2015, 136: 2369-2377. doi:  10.1002/ijc.29274
    [53] Shu X, Jiang Y, Wen T, et al. Association of hormone replacement therapy with increased risk of meningioma in women: A hospital-based multicenter study with propensity score matching[J]. Asia Pac J Clin Oncol, 2019, 15: e147-e153. doi:  10.1111/ajco.13138
  • 加载中
计量
  • 文章访问数:  90
  • HTML全文浏览量:  16
  • PDF下载量:  35
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-12-01
  • 录用日期:  2021-01-06
  • 刊出日期:  2021-05-30

目录

    /

    返回文章
    返回